Allogene Therapeutics, Inc. (ALLO) registered a loss of 38 cents per share in first-quarter 2024, in line with the Zacks Consensus Estimate. In the year-ago quarter, the company reported a loss of 69 cents.ALLO recorded revenues of $0.02 million during the quarter, missing the Zacks Consensus Estimate of $0.04 million. Revenues were down 27% year over year.Quarter in DetailResearch & development (R&D) expenses were $52.3 million, down 35% from the year-ago quarter’s level.General and administrative (G&A) ex ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2024 Earnings Conference Call May 13, 2024 5:00 PM ET Company Participants Christine Cassiano - Chief Corporate Affairs & Brand Strategy Officer David Chang - President & Chief Executive Officer Geoff Parker - Chief Financial Officer Zachary Roberts - EVP, Research & Development and Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Tyler Van Buren - TD Cowen Salveen Richter - Goldman Sachs Reni Benjamin - Citizens JMP Luca Issi - RBC Capi ...

Allogene Therapeutics (ALLO) came out with a quarterly loss of $0.38 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.68 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this immuno-oncology company would post a loss of $0.47 per share when it actually produced a loss of $0.43, delivering a surprise of 8.51%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Allogene Therapeuti ...

SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwritten offering of 37,931,035 shares of its common stock at a price of $2.90 per share. The gross proceeds from this offering are expected to be approximately $110 million, before deducting the underwriting discount and comm ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________________ FORM 10-Q ________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 ...

Exhibit 99.1 Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update • Cemacabtagene Ansegedleucel (Cema-Cel) ◦ Expanded CD19 Oncology Rights to Include all EU Member States and the United Kingdom, Reinforcing Company’s Conviction in the Unique Opportunity in Large B Cell Lymphoma (LBCL) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) ▪ Extended Territory Rights Substantially Increase Market Opportunity in 1L Consolidation LBCL and R/R CLL From More Than $6 Bi ...

Cemacabtagene Ansegedleucel (Cema-Cel) Expanded CD19 Oncology Rights to Include all EU Member States and the United Kingdom, Reinforcing Company's Conviction in the Unique Opportunity in Large B Cell Lymphoma (LBCL) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Extended Territory Rights Substantially Increase Market Opportunity in 1L Consolidation LBCL and R/R CLL From More Than $6 Billion in the US to More Than $9.5 Billion in the Combined U.S., EU Member States and the United KingdomCon ...

Conference Call and Webcast Scheduled for May 13, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report first quarter 2024 financial results and provide a business update on May 13, 2024, after the close of the market. The announcement will be foll ...

$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)ALLO-316 Illustrates Proof-of-Concept in RCC and the Potential of Dagger® Technology to Optimize CAR T Cell Expansion and Persistence SOUTH SAN FRANCISCO, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer ...

Investing in the technologies of tomorrow can be a lucrative investment strategy. If investors can discern trends as they develop, they can stay ahead of the curve and reap the rewards. This is what made Cathie Wood and her firm ARK Invest famous. Her funds invest in companies she "expect[s] to be the leaders, enablers, and beneficiaries of disruptive innovation."Wood's big bets have won her a lot of fans, but it hasn't always been a smooth ride. Investing in the cutting-edge means investing in what is larg ...